This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

J. ALASTAIR DUDGEON, MD

Am J Dis Child. 1978;132(8):748-750.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

During the early stages of clinical trials with live attenuated rubella vaccines about a decade ago, two important questions were paramount in the minds of those responsible for those trials. The first was concerned with the possible communicability of the vaccine virus and the second with the duration of immunity. It must be accepted that any new vaccine poses problems, both general and specific, but as far as rubella vaccines were concerned, these were of special importance.

The first question arose from the original trials in a small group of susceptible children carried out by Parkman et al¹ and Meyer et al² with their high passage virus (HPV-77) prepared in monkey kidney cell cultures. They had shown that intermittent excretion of rubella vaccine virus occurred in the majority of vaccinated individuals. The question was simple. If vaccinees excreted virus in the nasopharynx, could infection be transmitted to susceptible . . . [Full Text PDF of this Article]

Author Affiliations
Department of Microbiology Hospital for Sick Children Great Ormond Street London WC1N 3JH, United Kingdom

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?